Comparative Evaluation of Mustadi Yog versus Placebo for Pediatric Respiratory Allergic Disorders: A Double‑Blind Randomized Study

Abstract

Background:

Conventional management of pediatric respiratory allergic disorders (RADS) relies on antihistamines and bronchodilators, often with undesirable side effects. Mustadi Yog, a classical Ayurvedic polyherbal formulation, may offer safe adjunctive benefits.

Methods:

This prospective, double blind, randomized, placebo controlled trial was conducted over 12 months (April 2018 through March 2019) in the Post Graduate Department of Prasuti & Stri Roga at Nitishwar Ayurved Medical College & Hospital, Muzaffarpur, Bihar, India.  60 children (6–12 years) with physician diagnosed RADS were assigned 1:1 to Mustadi Yog (Group A, n = 30) or identical placebo (Group B, n = 30) twice daily for 8 weeks, alongside standard symptomatic care. The primary endpoint was change in total symptom score (sneezing, nasal congestion, cough) from baseline to Week 8. Secondary endpoints included frequency of exacerbations and Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) scores. Safety was monitored via adverse event reporting and routine hematology/biochemistry.

Results:

Mustadi Yog produced a significantly greater reduction in total symptom scores versus placebo (p < 0.05). The treatment arm experienced fewer and shorter exacerbations requiring rescue medication (p < 0.05) and demonstrated superior improvements in PRQLQ domains of symptoms, daily functioning, and emotional well being (p < 0.05). No serious adverse events occurred; laboratory parameters remained stable.

Conclusion:

Mustadi Yog is a safe, well tolerated adjunct that substantially reduces symptoms, decreases exacerbation risk, and enhances quality of life in children with RADS.